MedTrace Logo

To Demonstrate the Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions

NCT00947063 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability study of Promethazine HCl 50 mg tablets under fasting conditions.

Conditions

  • Allergy

Interventions

DRUG

Promethazine HCl 50 mg Tablets (Sandoz, Inc)

DRUG

Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)

Sponsors & Collaborators

Principal Investigators

  • Irwin Plisco, M.D. · Cetero Research, San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2004-08-31
Completion
2004-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00947063 on ClinicalTrials.gov